Salgia NJ - Search Results

1

Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.

Zengin ZB, Chehrazi-Raffle A, Salgia NJ, Muddasani R, Ali S, Meza L, Pal SK. Zengin ZB, et al. Among authors: salgia nj. Urol Oncol. 2022 Feb;40(2):25-36. doi: 10.1016/j.urolonc.2021.10.003. Epub 2021 Nov 26. Urol Oncol. 2022. PMID: 34840077 Review.

2

Editorial Comment.

Salgia NJ, Pal SK. Salgia NJ, et al. J Urol. 2019 Mar;201(3):548. doi: 10.1097/01.JU.0000553713.64297.bb. J Urol. 2019. PMID: 30759699 No abstract available.

3

The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.

Salgia NJ, Dara Y, Bergerot P, Salgia M, Pal SK. Salgia NJ, et al. Among authors: salgia m. Curr Treat Options Oncol. 2019 Apr 1;20(5):41. doi: 10.1007/s11864-019-0638-1. Curr Treat Options Oncol. 2019. PMID: 30937639 Review.

4

A drug delivery perspective on intratumoral-immunotherapy in renal cell carcinoma.

Meng WS, Salgia NJ, Pham NB, Velankar KY, Pal SK. Meng WS, et al. Among authors: salgia nj. Urol Oncol. 2021 Jun;39(6):338-345. doi: 10.1016/j.urolonc.2020.03.018. Epub 2020 May 10. Urol Oncol. 2021. PMID: 32402767 Review.

5

Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices.

Salgia NJ, Philip EJ, Ziari M, Yap K, Pal SK. Salgia NJ, et al. J Clin Med. 2020 May 17;9(5):1508. doi: 10.3390/jcm9051508. J Clin Med. 2020. PMID: 32429554 Free PMC article.

6

Tivozanib in renal cell carcinoma: a new approach to previously treated disease.

Salgia NJ, Zengin ZB, Pal SK. Salgia NJ, et al. Ther Adv Med Oncol. 2020 May 22;12:1758835920923818. doi: 10.1177/1758835920923818. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32547647 Free PMC article. Review.

7

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis.

Dizman N, Lyou Y, Salgia N, Bergerot PG, Hsu J, Enriquez D, Izatt T, Trent JM, Byron S, Pal S. Dizman N, et al. J Immunother Cancer. 2020 Jul;8(2):e000953. doi: 10.1136/jitc-2020-000953. J Immunother Cancer. 2020. PMID: 32661119 Free PMC article.

8

Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors.

Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK, Pal SK. Salgia NJ, et al. Eur Urol. 2020 Oct;78(4):498-502. doi: 10.1016/j.eururo.2020.07.011. Epub 2020 Aug 19. Eur Urol. 2020. PMID: 32828600

9

Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer.

Zengin ZB, Salgia NJ, Chehrazi-Raffle A, Meza L, Malhotra J, Pal SK. Zengin ZB, et al. Among authors: salgia nj. Cancer J. 2020 Sep/Oct;26(5):432-440. doi: 10.1097/PPO.0000000000000473. Cancer J. 2020. PMID: 32947311 Review.

10

Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status.

Bergerot CD, Philip EJ, Bergerot PG, Hsu J, Dizman N, Salgia M, Salgia N, Vaishampayan U, Battle D, Loscalzo M, Dale W, Pal SK. Bergerot CD, et al. Cancer. 2021 Feb 1;127(3):354-358. doi: 10.1002/cncr.33238. Epub 2020 Oct 2. Cancer. 2021. PMID: 33007114 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters